November 11, 2026

Abbott has received U.S. Food and Drug Administration (FDA) approval and CE Mark for the UltiSynq defibrillation lead, which is designed to deliver both conduction system pacing and defibrillation therapy, providing an additional lead option in the U.S. and EU for patients who are candidates for both conduction system pacing and defibrillation protection.